Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - BG Medicine, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R15.htm
EX-32 - EX-32 - BG Medicine, Inc.d398643dex32.htm
EX-10.1 - EX-10.1 - BG Medicine, Inc.d398643dex101.htm
EX-31.2 - EX-31.2 - BG Medicine, Inc.d398643dex312.htm
EX-10.2 - EX-10.2 - BG Medicine, Inc.d398643dex102.htm
10-Q - FORM 10-Q - BG Medicine, Inc.d398643d10q.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R3.htm
EX-31.1 - EX-31.1 - BG Medicine, Inc.d398643dex311.htm
v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Revenue:        
Product revenue $ 610 $ 87 $ 1,592 $ 144
Service revenue 31 92 151 1,111
Total revenue 641 179 1,743 1,255
Costs and Operating Expenses:        
Cost of product revenue 209 31 552 48
Cost of service revenue 31 53 151 380
Research and development 2,549 1,936 7,662 6,010
Selling, general and administrative 4,388 3,072 13,501 7,567
Total costs and operating expenses 7,177 5,092 21,866 14,005
Loss from operations (6,536) (4,913) (20,123) (12,750)
Interest income 9 10 17 25
Interest expense (302)   (779) (90)
Other income (expense) 15 22 15 (33)
Net loss (6,814) (4,881) (20,870) (12,848)
Accretion of redeemable convertible preferred stock       (118)
Net loss attributable to common stockholders $ (6,814) $ (4,881) $ (20,870) $ (12,966)
Net loss attributable to common stockholders per share - basic and diluted $ (0.34) $ (0.25) $ (1.04) $ (0.77)
Weighted-average common shares outstanding used in computing per share amounts - basic and diluted 20,320,190 19,344,905 20,118,768 16,925,693